Quote:

---

If you add an ICI at this point to the phase 2 then there could be some ambiguity as to whether it was LL or the ICI that actually showed the improvement. That's the tactic being taken on StockTwits by Mazzy saying that the mTNBC results are due to the ICI and not LL. ;

---

Mazzy is a trolling idiot. A Pd-L1 inhibitor does nothing when PD-L1 is absent in the cold tumors. Leronlimab's activation of PD-L1 is due to the switch from an M2 tumor protectant macrophage phentotype to M1. The M1 macrophages will do damage on their own but are hampered by the PD-L1 tumor protection. A PD-L1 inhibitor allows the M1 macrophages to attack in full force. The key to the entire thing is the switch from M2 to M1 which is what leronlimab accomplishes.